2024-01-23 03:22:09 ET
Summary
- Briumvi shows increasing revenues but faces decelerating growth, suggesting possible market saturation or increased competition.
- TG Therapeutics has a strong balance sheet but contends with high SG&A costs, typical in early-stage commercialization.
- Market sentiment is mixed, with high analyst growth predictions but bearish investor moods and significant short interest.
- TGTX stock remains a "Hold" with cautious optimism; near-term stock performance may be stagnant, but company fundamentals show promise.
At a Glance
My last article for TG Therapeutics ( TGTX ) focused on Briumvi's rocky journey in the multiple sclerosis [MS] arena, leading to a cautious "Hold" stance. ...
Read the full article on Seeking Alpha
For further details see:
TG Therapeutics: Indications Of Slowing Market Growth For Briumvi